These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12388851)

  • 1. Refinement, reduction, and replacement of animal use for regulatory testing: current best scientific practices for the evaluation of safety and potency of biologicals.
    Hendriksen CF
    ILAR J; 2002; 43 Suppl():S43-8. PubMed ID: 12388851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The international symposium on regulatory testing and animal welfare: recommendations on best scientific practices for biological: safety and potency evaluations.
    Cussler K; Kulpa J; Calver J
    ILAR J; 2002; 43 Suppl():S126-8. PubMed ID: 12388866
    [No Abstract]   [Full Text] [Related]  

  • 3. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals.
    Lilley E; Isbrucker R; Ragan I; Holmes A
    Biologicals; 2021 Nov; 74():24-27. PubMed ID: 34750045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ECVAM's role in the implementation of the Three Rs concept in the field of biologicals.
    Hendriksen C; Cussler K; Halder M
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():41-6. PubMed ID: 12513650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement, reduction, and replacement of animal use for regulatory testing: future improvements and implementation within the regulatory framework.
    Richmond J
    ILAR J; 2002; 43 Suppl():S63-8. PubMed ID: 12388854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory processes and three Rs alternatives.
    Milstien J
    Dev Biol (Basel); 2002; 111():15-9. PubMed ID: 12678220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency testing of veterinary vaccines: the way from in vivo to in vitro.
    Romberg J; Lang S; Balks E; Kamphuis E; Duchow K; Loos D; Rau H; Motitschke A; Jungbäck C
    Biologicals; 2012 Jan; 40(1):100-6. PubMed ID: 22075457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of the 3Rs (refinement, reduction, and replacement): validation and regulatory acceptance considerations for alternative toxicological test methods.
    Schechtman LM
    ILAR J; 2002; 43 Suppl():S85-94. PubMed ID: 12388858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ECVAM's contributions to the implementation of the Three Rs in the production and quality control of biologicals.
    Halder M; Hendriksen C; Cussler K; Balls M
    Altern Lab Anim; 2002; 30(1):93-108. PubMed ID: 11827574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in animal use in the production and testing of biologicals.
    Festing MF
    Dev Biol Stand; 1999; 101():195-200. PubMed ID: 10566793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ensuring quality of in vitro alternative test methods: Current practice.
    Rispin A; Stitzel K; Harbell J; Klausner M
    Regul Toxicol Pharmacol; 2006 Jul; 45(2):97-103. PubMed ID: 16644076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The five Rs: refinement, reduction, replacement. A regulatory revolution.
    Lucken RN
    Dev Biol Stand; 1996; 86():67-72. PubMed ID: 8785993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of two serological methods for potency testing of whole cell pertussis vaccines.
    von Hunolstein C; Gomez Miguel MJ; Pezzella C; Scopetti F; Behr-Gross ME; Halder M; Hoffmann S; Levels L; van der Gun J; Hendriksen C
    Pharmeuropa Bio; 2008 Dec; 2008(1):7-18. PubMed ID: 19220977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.